Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.

Kai-Uwe EckardtRajiv AgarwalAhmad AswadAhmed AwadGeoffrey A BlockMarcelo R BacciYoussef M K FaragSteven FishbaneHarold HubertAlan JardineZeeshan KhawajaMark J KouryBradley J MaroniKunihiro MatsushitaPeter A McCulloughEldrin F LewisWenli LuoPatrick S ParfreyPablo PergolaMark J SarnakBruce SpinowitzJames TumlinDennis L VargoKimberly A WaltersWolfgang C WinkelmayerJanet WittesRafal ZwiechGlenn M Chertow

Published in: The New England journal of medicine (2021)

Among patients with anemia and CKD who were undergoing dialysis, vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; INNO2VATE ClinicalTrials.gov numbers, NCT02865850 and NCT02892149.).

Keyphrases

chronic kidney disease
end stage renal disease
patients undergoing
small molecule
red blood cell